85-1561-89　Bortezomib, Free Base 25mg　CAS No:179324-69-7　B2572-02

特徴

• Bortezomib is the active ingredient in the drug sold under the trade name Velcade®. This drug has been approved in at least one country to treat multiple myeloma. It is a potent (Ki, 0.6nM), specific and reversible proteasome inhibitor. There is not any significant inhibitory activity against other enzymes or receptors. In a study with the National Cancer Institute's panel of 60 human cell lines, Bortezomib showed a mean IC50 of 7nM as tested by SRB analysis
• Bortezomib is active in preclinical models of human prostate cancer, while its effects on apoptosis versus angiogenesis are cell type dependent. Bortezomib caused comparable growth suppression in LNCaP-Pro5 and PC3M-Pro4 cells with an IC90 of 10nM. Bortezomib inhibits cell proliferation of H460 cells (Human non-small cell lung cancer cell lines) with an IC50 of 0.1uM.
• Synonyms:Velcade; MG-341; PS-341; [(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic Acid
• Molecular Formula:C19H25BN4O4
• Molecular Weight:384.24
• Purity:HPLC: ~99%; TLC: ~99%
• Appearance:White to off-white powder
• Melting Point:As Reported
• Solubility:Soluble in DMSO at 200mg/ml. Soluble in ethanol at 200mg/ml. Very poorly soluble in water. Maximum solubility in plain water is estimated to be about 5-10uM.
• Storage and Stability:May be stored at RT for short-term only. Long-term storage is recommended at -20°C. Stable for 12 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.